Adair Newhall


Adair is a Principal at Greenspring Associates and is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. Adair currently serves on the Bright Health and Crown Labs Boards & as an Observer on the Paladina Health Board. Adair previously served as a Principal at Domain Associates, a leading healthcare focused venture capital firm and Greenspring Associates fund manager. At Domain Associates, he held board observer positions with several portfolio companies including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals and Xagenic. He was previously involved as a board observer with Otonomy (NASDAQ: OTIC), which completed a successful initial public offering in August 2014. Prior to joining Domain Associates in August 2009, Adair worked in the Business Development group at Esprit Pharma where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan (NYSE: AGN) for $370 million. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $514 million. He received his M.B.A from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania.

Currently, Adair is a Kauffman Fellow and a co-founder of the UVa Venture Summit.